Literature DB >> 20884709

Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.

Carlos Fernández de Larrea1, Natalia Tovar, M Teresa Cibeira, Juan I Aróstegui, Laura Rosiñol, Montserrat Elena, Xavier Filella, Jordi Yagüe, Joan Bladé.   

Abstract

The emergence of oligoclonal bands is associated with a favorable outcome after autologous stem cell transplantation in multiple myeloma. The aim of this study was to determine the prevalence of immunoglobulin oligoclonality in 33 patients with multiple myeloma in complete remission achieved with primary therapy with either cytotoxic agents (n = 18, 54.5%) or new induction regimens incorporating novel drugs (n = 15, 45.4%). Eleven patients (33.3%) developed oligoclonal bands. In the group treated with novel agents, this oligoclonal immune response was observed in 60% (9 of 15) of the patients versus only 11.1% (2 of 18) of those given cytotoxic therapy (P = 0.003). This is the first report showing a different frequency of oligoclonal humoral response in patients in complete remission achieved after conventional cytotoxic therapy versus induction incorporating novel agents. This difference could be due to a higher antitumor effect associated with the use of novel drugs, a stronger immune reconstitution, or both.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884709      PMCID: PMC3012783          DOI: 10.3324/haematol.2010.030882

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

1.  Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.

Authors:  S Hovenga; J T de Wolf; J E Guikema; H Klip; J W Smit; C T Smit Sibinga; N A Bos; E Vellenga
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

2.  Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.

Authors:  Carlos Fernández de Larrea; María Teresa Cibeira; Montserrat Elena; Juan Ignacio Arostegui; Laura Rosiñol; Montserrat Rovira; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Blood       Date:  2009-10-01       Impact factor: 22.113

3.  Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.

Authors:  C S Zent; C S Wilson; G Tricot; S Jagannath; D Siegel; K R Desikan; N Munshi; D Bracy; B Barlogie; A W Butch
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation.

Authors:  J E Guikema; E Vellenga; J M Veeneman; S Hovenga; M H Bakkus; H Klip; N A Bos
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Authors:  Tomer Mark; David Jayabalan; Morton Coleman; Roger N Pearse; Y Lynn Wang; Richard Lent; Paul J Christos; Joong W Lee; Yash P Agrawal; Susan Matthew; Scott Ely; Madhu Mazumdar; Ethel Cesarman; John P Leonard; Richard R Furman; Selina Chen-Kiang; Ruben Niesvizky
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

7.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Tommaso Caravita; Emanuela Merla; Vincenzo Capparella; Vincenzo Callea; Clotilde Cangialosi; Mariella Grasso; Fausto Rossini; Monica Galli; Lucio Catalano; Elena Zamagni; Maria Teresa Petrucci; Valerio De Stefano; Manuela Ceccarelli; Maria Teresa Ambrosini; Ilaria Avonto; Patrizia Falco; Giovannino Ciccone; Anna Marina Liberati; Pellegrino Musto; Mario Boccadoro
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

8.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Authors:  Thierry Facon; Jean Yves Mary; Cyrille Hulin; Lotfi Benboubker; Michel Attal; Brigitte Pegourie; Marc Renaud; Jean Luc Harousseau; Gaëlle Guillerm; Carine Chaleteix; Mamoun Dib; Laurent Voillat; Hervé Maisonneuve; Jacques Troncy; Véronique Dorvaux; Mathieu Monconduit; Claude Martin; Philippe Casassus; Jérôme Jaubert; Henry Jardel; Chantal Doyen; Brigitte Kolb; Bruno Anglaret; Bernard Grosbois; Ibrahim Yakoub-Agha; Claire Mathiot; Hervé Avet-Loiseau
Journal:  Lancet       Date:  2007-10-06       Impact factor: 79.321

9.  Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

Authors:  Antonio Palumbo; Patrizia Falco; Paolo Corradini; Antonietta Falcone; Francesco Di Raimondo; Nicola Giuliani; Claudia Crippa; Giovannino Ciccone; Paola Omedè; Maria Teresa Ambrosini; Francesca Gay; Sara Bringhen; Pellegrino Musto; Robin Foà; Robert Knight; Jerome B Zeldis; Mario Boccadoro; Maria Teresa Petrucci
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

View more
  12 in total

1.  Lack of correlation between emergence of an abnormal protein band or of oligoclonal bands and survival in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation.

Authors:  Elizabeth Byrne; Chrissy Giles; Joanne Andrews; Amin Rahemtulla; Kikkeri N Naresh
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

2.  Emergence of Oligoclonal Bands in Association with the use of Chemotherapy and Hematopoietic Stem Cell Transplantation.

Authors:  Chandramallika Paul; Sarit Chakraborty; Subhosmito Chakraborty
Journal:  Indian J Clin Biochem       Date:  2021-05-19

3.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

4.  Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Authors:  Natalia Tovar; Carlos Fernández de Larrea; Juan I Aróstegui; Maria Teresa Cibeira; Laura Rosiñol; Montserrat Rovira; Montserrat Elena; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

5.  oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.

Authors:  Manabu Fujisawa; Keisuke Seike; Kouta Fukumoto; Yasuhito Suehara; Masafumi Fukaya; Hiroki Sugihara; Masami Takeuchi; Kosei Matsue
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

6.  Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Authors:  H Ludwig; D Milosavljevic; N Zojer; J M Faint; A R Bradwell; W Hübl; S J Harding
Journal:  Leukemia       Date:  2012-07-17       Impact factor: 11.528

7.  Audit of the Prevalence of Noncorrelation of Immunofixation with Protein Electrophoresis and Serum Free Light Chain Assays in Multiple Myeloma in a Tertiary Cancer Care Center.

Authors:  Chandramallika Paul; Subhosmito Chakraborty; S Sugumar; Ranjan Bhattacharya; Sandip Rath; Sarit Chakraborty
Journal:  Indian J Clin Biochem       Date:  2020-09-15

8.  Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Authors:  R Silvennoinen; T Lundan; V Kairisto; T-T Pelliniemi; M Putkonen; P Anttila; V Huotari; P Mäntymaa; S Siitonen; L Uotila; T-L Penttilä; V Juvonen; T Selander; K Remes
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

9.  Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2017-07-01

10.  For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission.

Authors:  Luiza Soares Vieira da Silva; Edvan de Queiroz Crusoe; Lais Rocha Guimarães de Souza; Carlos Sérgio Chiattone; Vânia Tietsche de Moraes Hungria
Journal:  Rev Bras Hematol Hemoter       Date:  2017-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.